See the article here: SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia
See the article here: SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia
Follow this link: Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
Here is the original post: Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
Doctors encouraged by early-stage trial of MS stem cell therapy The Guardian
Stem cell-based treatment controls blood sugar in people with Type ... Science Daily
Scientists create 'cloaked' donor cell and tissue grafts that escape rejection by the immune system Medical Xpress
How ChatGPT is changing the health care industry, medicine Axios
Dr Weber on the Prognostic Utility of ctDNA Dynamics in Melanoma OncLive
Where Is Paolo Macchiarini Today? The Disgraced Surgeon Was ... Bustle
A call to adapt the regulation of HLA testing for T cell receptor-based ... Nature.com
Recent Comments